OLR1 and atherosclerosis: Molecular therapeutic approaches, such as antibodies, antisense oligonucleotides, siRNA, and miRNA, are fast-emerging tools of biotechnology that may inhibit LOX-1 and its splice isoforms laying a foundation for the development of therapeutic strategies against atherosclerosis and tumors linked to LOX-1 overexpression.